Literature DB >> 18160946

Profile of viral hepatitis A, B, and C in a Saudi Arabian hospital.

Jaffar A Al-Tawfiq1, Adnan Anani.   

Abstract

BACKGROUND: The objective of the study was to investigate the pattern and epidemiology of viral hepatitis among patients of the Saudi Aramco Medical Services Organization (SAMSO) in the Eastern Province of Saudi Arabia. MATERIAL/
METHODS: A retrospective analysis of the reported cases of viral hepatitis was conducted from January 2000 to June 2005.
RESULTS: A total of 1214 patients with viral hepatitis were identified during the study period. Of hepatitis A, B, and C, HBV was the most predominant type of hepatitis, accounting for 49.3% of the cases, followed by HCV (40.7%) and HAV (10%). Nine (0.7%) patients had both HBV and HCV. The male-to-female ratio was higher in HBV (1.8:1), whereas HAV and HCV showed no significant differences. HAV infection predominates in children (1-20 years), HBV in young adults (31-50 years), and HCV in older adults (51-70 years).
CONCLUSIONS: HBV continues to be the most predominant type of viral hepatitis and is a disease of adults, whereas HCV is mainly a disease of older adults. Continued surveillance of hepatitis cases is needed to further delineate the risk factors and to establish effective preventive strategies.

Entities:  

Mesh:

Year:  2008        PMID: 18160946

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  15 in total

1.  Distribution of hepatitis C virus (HCV) genotypes in a Saudi Arabian hospital during the 2015-2020 period.

Authors:  Fadel Ali M Almosa; Ali Hassan A Alnasser; Jaffar A Al-Tawfiq
Journal:  Infez Med       Date:  2021-09-10

2.  Confirmed Foodborne Hepatitis A in Saudi Arabia, 2005-2015.

Authors:  Jaber Sharaheeli; Bader Alibrahim
Journal:  Cureus       Date:  2022-01-02

Review 3.  The Emergent Concern of Hepatitis B globally with special attention to Kingdom of Saudi Arabia.

Authors:  Ahmad N Aljarbou
Journal:  Int J Health Sci (Qassim)       Date:  2013-11

4.  SASLT practice guidelines: management of hepatitis C virus infection.

Authors:  Abdullah S Alghamdi; Faisal M Sanai; Mona Ismail; Hamdan Alghamdi; Khalid Alswat; Adel Alqutub; Ibrahim Altraif; Hemant Shah; Faleh Z Alfaleh
Journal:  Saudi J Gastroenterol       Date:  2012-09       Impact factor: 2.485

5.  Prevalence of hepatitis A across various countries in the Middle East, African and Eastern European countries.

Authors:  Abbolmajid Ghasemian
Journal:  Caspian J Intern Med       Date:  2016

6.  Prevalence of hepatitis-C virus genotypes and potential transmission risks in Malakand Khyber Pakhtunkhwa, Pakistan.

Authors:  Nausheen Nazir; Muhammad Rasul Jan; Amjad Ali; Muhammad Asif; Muhammad Idrees; Mohammad Nisar; Muhammad Zahoor; Naser M Abd El-Salam
Journal:  Virol J       Date:  2017-08-22       Impact factor: 4.099

Review 7.  Epidemiology of viral hepatitis in Saudi Arabia: are we off the hook?

Authors:  Ayman A Abdo; Faisal M Sanai; Faleh Z Al-Faleh
Journal:  Saudi J Gastroenterol       Date:  2012 Nov-Dec       Impact factor: 2.485

Review 8.  A review of the experience of childhood hepatitis A vaccination in Saudi Arabia and Turkey: implications for hepatitis A control and prevention in the Middle East and North African region.

Authors:  Selim Badur; Serdar Öztürk; Alev Ozakay; Mansour Khalaf; Debasish Saha; Pierre Van Damme
Journal:  Hum Vaccin Immunother       Date:  2021-07-02       Impact factor: 4.526

9.  Seroprevalence of hepatitis B and C virus infections among health students and health care workers in the Najran region, southwestern Saudi Arabia: the need for national guidelines for health students.

Authors:  Jobran M Alqahtani; Saeed A Abu-Eshy; Ahmed A Mahfouz; Awad A El-Mekki; Ahmed M Asaad
Journal:  BMC Public Health       Date:  2014-06-09       Impact factor: 3.295

10.  The declining rates of hepatitis B carriage among adolescents and young people in the Eastern region of Saudi Arabia.

Authors:  Khalid M Al-Jubran; Mohamed A Al-Dossary; Salah H Elsafi
Journal:  Saudi Med J       Date:  2016-08       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.